AIDS and HIV Information
Triumeq Side Effects Treatment Risks and Benefits
What are the side effects of Triumeq?
The pairing of DTG with abacavir can be problematic in some cases. Before initiating Triumeq regimen, testing is required, and patients who test positive are disqualified from taking the regimen because of high potential of abacavir to cause a hypersensitivity reaction.
Common Side Effects
- Trouble sleeping
Less Common Side Effects
- Abdominal pain
- Fat redistribution
Possible Serious Side Effects
Hepatotoxicity has been reported with dolutegravir use. Advice patients to monitor hepatotoxity while on Triumeq regimen.
Lactic acidosis or hepatomegaly
Triumeq may cause a serious condition, which can damage the liver. Watch out for signs and symptoms of deep and rabid berating, vomiting, nausea, and stomach pain.
Exacerbation of existing Hepatitis B and C
After stopping the treatment, worsening of hepatitis B or C were seen in some patients. Patients must seek medical help if they are experiencing signs of liver problems, such as jaundice, yellowing of eyes and dark urine.
Immune reconstitution syndrome
This often occurs within the first few months of starting treatment. Patients who are taking Triumeq may suddenly trigger their immune system to strongly react with unresolved infections in the body.
Increased risk of heart attack
Risk of myocardial infarction has been reported in a number of studies, but not in others. Do not take Triumeq if you’re taking anti-arrhythmic drugs such as Dofetilide.
Compared to other single-tablet regimen containing the active ingredient tenofovir, or the pharmacokinetic enhancer cobicistat, drug interactions are minimal. The absence of TDF, makes Triumeq safer and more potent than other NRTI-containing HIV medications.
- Triumeq FDA Label - Tablet, film coated. AIDSinfo. 2018. Available at: https://aidsinfo.nih.gov/drugs/534/triumeq/169/professional. Accessed June 20, 2018.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 20, 2018.